<DOC>
	<DOCNO>NCT00466947</DOCNO>
	<brief_summary>This study large number healthy child le 3 year old measure efficacy GlaxoSmithKline ( GSK ) Biologicals ' 10-valent pneumococcal conjugate candidate vaccine ( Synflorix vaccine , GSK1024850A ) prevent case pneumonia ( lung infection ) likely cause bacteria ( Streptococcus pneumoniae Haemophilus influenzae ) case otitis medium ( ear infection ) child 3 year old .</brief_summary>
	<brief_title>COMPAS ( Clinical Otitis Media &amp; Pneumonia Study ) : Pneumonia &amp; Acute Otitis Media ( AOM ) Efficacy Study Pneumococcal Conjugate Vaccine</brief_title>
	<detailed_description>The Protocol Posting update order comply FDA Amendment Act , Sep 2007 . The following vaccine offer sponsor : - Two dos hepatitis A vaccine offer subject comply national recommendation . - NeisVac-C vaccine Neisseria meningitis group C offer subject Argentina 12 month age . - Varicella vaccine offer subject Colombia Panama 12 month age . - Two dos Rotarix vaccine offer subject Colombia within first six month life . In addition , subject receive dose Hepatitis B vaccine birth accord national recommendation dose measles , mumps rubella ( MMR ) vaccine 12 15 month age accord local Extended Program Immunization ( EPI ) . These vaccine provide sponsor . The protocol posting update accord amendment protocol date 25 Nov 2008 . The protocol posting update accord amendment protocol date 14 December 2009 . The protocol posting update accord amendment protocol date 09 September 2010 .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>A male female , include , 6 16 week age time first vaccination . Preterm born infant include study start 8 week chronological age time first vaccination 16 week chronological age Subjects live area cover surveillance system community acquire pneumonia ( CAP ) , invasive disease acute otitis medium ( AOM ) •Written inform consent obtain parent guardian subject . Free know suspected health problem ( establish medical history clinical examination enter study ) , would contraindicate initiation routine immunization outside clinical trial context . Subjects investigator believe parents/guardians comply requirement protocol Use investigational nonregistered drug plan use study period . Use plan use investigational nonregistered vaccine study vaccine ( ) . Previous vaccination diphtheria , tetanus , pertussis , Haemophilus influenzae type b , hepatitis A and/or Streptococcus . pneumoniae . Locally recommend EPI vaccine give birth allow , administer least one month first dose study vaccine .Other locally recommend vaccine always allow , even concomitantly administer study vaccine . •Previous planned vaccination register pneumococcal vaccine Prevnar allow . If Prevnar immunization need initiate , due presence high risk disease pneumococcal infection Prevnar vaccine make locally available , subject enrol study refer specific Prevnar immunization program . History allergic disease reaction likely exacerbate component vaccine . History neurologic disorder seizure . Acute disease time enrolment For Colombia : infant low birth weight ( less ( &lt; ) 2.500 gram )</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Otitis medium</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Community acquire pneumonia ( CAP )</keyword>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Booster vaccination</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Carriage</keyword>
</DOC>